XERS - Xeris Pharmaceuticals net loss narrows as Q2 results beat on bottom line
- Xeris ( NASDAQ: XERS ) Pharmaceuticals saw its Q2 2022 net loss narrow ~4% to $26.2M as the biotech beat on the bottom line .
- Although revenue of ~$320M was a ~49% year-over-year increase, it was a slight miss.
- Sales of the company's biggest selling product, Gvoke (glucagon injection), increase 42% to $23.9M.
- Total costs in the quarter of $44.2M was a ~27% increase compared to Q1 2021.
- Check out Seeking Alpha contributor Andy Jones' bullish argument for Xeris ( XERS ).
For further details see:
Xeris Pharmaceuticals net loss narrows as Q2 results beat on bottom line